Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
MissionIR would like to highlight MannKind Corporation, a publicly traded development stage biopharmaceutical company, engaged in the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate, AFREZZA inhalation powder, an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.
In the company?s news last week,
MannKind announced it has finalized the recruitment of patients for two Phase 3 clinical studies of AFREZZA (insulin human [rDNA origin]), which is an investigational, ultra rapid-acting mealtime insulin therapy administered through the company?s soon-to-be-marketed next-generation inhaler.
http://www.equities.com/news/news-headline-story?dt=2012-10-07&val=566014&d=1&cat=headline
Still not keen on the idea of inhaled insulin 😱
In the company?s news last week,
MannKind announced it has finalized the recruitment of patients for two Phase 3 clinical studies of AFREZZA (insulin human [rDNA origin]), which is an investigational, ultra rapid-acting mealtime insulin therapy administered through the company?s soon-to-be-marketed next-generation inhaler.
http://www.equities.com/news/news-headline-story?dt=2012-10-07&val=566014&d=1&cat=headline
Still not keen on the idea of inhaled insulin 😱